O	0	7	Patient
O	7	8	-
O	8	16	reported
O	17	25	outcomes
O	26	30	from
O	31	40	KATHERINE
O	40	41	:
O	42	43	A
O	44	49	phase
O	50	51	3
O	52	57	study
O	58	60	of
B-intervention	61	69	adjuvant
I-intervention	70	81	trastuzumab
I-intervention	82	91	emtansine
O	92	98	versus
B-control	99	110	trastuzumab
O	111	113	in
O	114	122	patients
O	123	127	with
O	128	136	residual
O	137	145	invasive
O	146	153	disease
O	154	159	after
O	160	171	neoadjuvant
O	172	179	therapy
O	180	183	for
O	184	189	human
O	190	199	epidermal
O	200	206	growth
O	207	213	factor
O	214	222	receptor
O	223	224	2
O	224	225	-
O	225	233	positive
O	234	240	breast
O	241	247	cancer
O	247	248	.

O	249	252	The
O	253	258	phase
O	259	260	3
O	261	270	KATHERINE
O	271	276	trial
O	277	289	demonstrated
O	290	303	significantly
O	304	312	improved
O	313	321	invasive
O	322	329	disease
O	329	330	-
O	330	334	free
O	335	343	survival
O	344	348	with
O	349	357	adjuvant
O	358	369	trastuzumab
O	370	379	emtansine
O	380	381	(
O	381	382	T
O	382	383	-
O	383	386	DM1
O	386	387	)
O	388	394	versus
O	395	406	trastuzumab
O	407	409	in
O	410	418	patients
O	419	423	with
O	424	428	HER2
O	428	429	-
O	429	437	positive
O	438	443	early
O	444	450	breast
O	451	457	cancer
O	458	461	and
O	462	470	residual
O	471	479	invasive
O	480	487	disease
O	488	493	after
O	494	505	neoadjuvant
O	506	518	chemotherapy
O	519	523	plus
O	524	528	HER2
O	528	529	-
O	529	537	targeted
O	538	545	therapy
O	545	546	.

B-eligibility	547	555	Patients
I-eligibility	556	559	who
I-eligibility	560	568	received
I-eligibility	569	575	taxane
I-eligibility	575	576	-
I-eligibility	577	580	and
I-eligibility	581	592	trastuzumab
I-eligibility	592	593	-
I-eligibility	593	603	containing
I-eligibility	604	615	neoadjuvant
I-eligibility	616	623	therapy
I-eligibility	624	625	(
I-eligibility	625	629	with
I-eligibility	629	630	/
I-eligibility	630	637	without
I-eligibility	638	652	anthracyclines
I-eligibility	652	653	)
I-eligibility	654	657	and
I-eligibility	658	661	had
I-eligibility	662	670	residual
I-eligibility	671	679	invasive
I-eligibility	680	687	disease
I-eligibility	688	689	(
I-eligibility	689	695	breast
I-eligibility	696	699	and
I-eligibility	699	700	/
I-eligibility	700	702	or
I-eligibility	703	711	axillary
I-eligibility	712	717	nodes
I-eligibility	717	718	)
I-eligibility	719	721	at
I-eligibility	722	729	surgery
O	730	734	were
O	735	743	randomly
O	744	752	assigned
O	753	755	to
O	756	758	14
O	759	765	cycles
O	766	768	of
O	769	777	adjuvant
O	778	779	T
O	779	780	-
O	780	783	DM1
O	784	785	(
O	785	786	3
O	786	787	.
O	787	788	6
O	789	791	mg
O	791	792	/
O	792	794	kg
O	795	808	intravenously
O	809	814	every
O	815	816	3
O	817	822	weeks
O	822	823	)
O	824	826	or
O	827	838	trastuzumab
O	839	840	(
O	840	841	6
O	842	844	mg
O	844	845	/
O	845	847	kg
O	848	861	intravenously
O	862	867	every
O	868	869	3
O	870	875	weeks
O	875	876	)
O	876	877	.

O	878	881	The
O	882	890	European
O	891	903	Organisation
O	904	907	for
O	908	916	Research
O	917	920	and
O	921	930	Treatment
O	931	933	of
O	934	940	Cancer
O	941	948	Quality
O	949	951	of
O	952	956	Life
O	957	970	Questionnaire
O	970	971	-
O	971	975	Core
O	976	978	30
O	979	980	(
O	980	983	QLQ
O	983	984	-
O	984	987	C30
O	987	988	)
O	989	992	and
O	993	999	breast
O	1000	1006	cancer
O	1007	1013	module
O	1014	1015	(
O	1015	1018	QLQ
O	1018	1019	-
O	1019	1023	BR23
O	1023	1024	)
O	1025	1029	were
O	1030	1039	completed
O	1040	1042	at
O	1043	1052	screening
O	1052	1053	,
O	1054	1056	at
O	1057	1060	day
O	1061	1062	1
O	1063	1065	of
O	1066	1072	cycles
O	1073	1074	5
O	1075	1078	and
O	1079	1081	11
O	1081	1082	,
O	1083	1089	within
O	1090	1092	30
O	1093	1097	days
O	1098	1103	after
O	1104	1109	study
O	1110	1114	drug
O	1115	1125	completion
O	1125	1126	,
O	1127	1130	and
O	1131	1133	at
O	1134	1135	6
O	1135	1136	-
O	1137	1140	and
O	1141	1143	12
O	1143	1144	-
O	1144	1149	month
O	1150	1156	follow
O	1156	1157	-
O	1157	1159	up
O	1160	1166	visits
O	1166	1167	.

O	1168	1170	Of
O	1171	1179	patients
O	1180	1183	who
O	1184	1188	were
O	1189	1197	randomly
O	1198	1206	assigned
O	1207	1209	to
O	1210	1211	T
O	1211	1212	-
O	1212	1215	DM1
O	1216	1217	(
O	1217	1218	n
O	1219	1220	=
B-intervention-participants	1221	1224	743
O	1224	1225	)
O	1226	1229	and
O	1230	1241	trastuzumab
O	1242	1243	(
O	1243	1244	n
O	1245	1246	=
B-control-participants	1247	1250	743
O	1250	1251	)
O	1251	1252	,
O	1253	1256	612
O	1257	1258	(
O	1258	1260	82
O	1260	1261	%
O	1261	1262	)
O	1263	1266	and
O	1267	1270	640
O	1271	1272	(
O	1272	1274	86
O	1274	1275	%
O	1275	1276	)
O	1276	1277	,
O	1278	1290	respectively
O	1290	1291	,
O	1292	1295	had
O	1296	1301	valid
O	1302	1310	baseline
O	1311	1314	and
O	1315	1316	≥
O	1316	1317	1
O	1318	1330	postbaseline
O	1331	1342	assessments
O	1342	1343	.

O	1344	1346	No
O	1347	1357	clinically
O	1358	1368	meaningful
O	1369	1376	changes
O	1377	1378	(
O	1378	1379	≥
O	1379	1381	10
O	1382	1388	points
O	1388	1389	)
O	1390	1394	from
O	1395	1403	baseline
O	1404	1406	in
O	1407	1411	mean
O	1412	1415	QLQ
O	1415	1416	-
O	1416	1419	C30
O	1420	1423	and
O	1424	1427	QLQ
O	1427	1428	-
O	1428	1432	BR23
O	1433	1439	scores
O	1440	1448	occurred
O	1449	1451	in
O	1452	1458	either
O	1459	1462	arm
O	1462	1463	.

O	1464	1468	More
O	1469	1477	patients
O	1478	1487	receiving
O	1488	1489	T
O	1489	1490	-
O	1490	1493	DM1
O	1494	1502	reported
O	1503	1513	clinically
O	1514	1524	meaningful
O	1525	1538	deterioration
O	1539	1541	at
O	1542	1545	any
O	1546	1556	assessment
O	1557	1562	point
O	1563	1565	in
B-outcome	1566	1570	role
I-outcome	1571	1582	functioning
O	1583	1584	(
B-iv-bin-percent	1584	1586	49
I-iv-bin-percent	1586	1587	%
O	1588	1590	vs
B-cv-bin-percent	1591	1593	41
I-cv-bin-percent	1593	1594	%
O	1594	1595	)
O	1595	1596	,
B-outcome	1597	1605	appetite
I-outcome	1606	1610	loss
O	1611	1612	(
B-iv-bin-percent	1612	1614	38
I-iv-bin-percent	1614	1615	%
O	1616	1618	vs
B-cv-bin-percent	1619	1621	28
I-cv-bin-percent	1621	1622	%
O	1622	1623	)
O	1623	1624	,
B-outcome	1625	1637	constipation
O	1638	1639	(
B-iv-bin-percent	1639	1641	47
I-iv-bin-percent	1641	1642	%
O	1643	1645	vs
B-cv-bin-percent	1646	1648	38
I-cv-bin-percent	1648	1649	%
O	1649	1650	)
O	1650	1651	,
B-outcome	1652	1659	fatigue
O	1660	1661	(
B-iv-bin-percent	1661	1663	66
I-iv-bin-percent	1663	1664	%
O	1665	1667	vs
B-cv-bin-percent	1668	1670	60
I-cv-bin-percent	1670	1671	%
O	1671	1672	)
O	1672	1673	,
B-outcome	1674	1680	nausea
I-outcome	1680	1681	/
I-outcome	1681	1689	vomiting
O	1690	1691	(
B-iv-bin-percent	1691	1693	39
I-iv-bin-percent	1693	1694	%
O	1695	1697	vs
B-cv-bin-percent	1698	1700	30
I-cv-bin-percent	1700	1701	%
O	1701	1702	)
O	1702	1703	,
O	1704	1707	and
B-outcome	1708	1716	systemic
I-outcome	1717	1724	therapy
I-outcome	1725	1729	side
I-outcome	1730	1737	effects
O	1738	1739	(
B-iv-bin-percent	1739	1741	49
I-iv-bin-percent	1741	1742	%
O	1743	1745	vs
B-cv-bin-percent	1746	1748	36
I-cv-bin-percent	1748	1749	%
O	1749	1750	)
O	1750	1751	.

O	1752	1757	These
O	1758	1769	differences
O	1770	1774	were
O	1775	1777	no
O	1778	1784	longer
O	1785	1793	apparent
O	1794	1796	at
O	1797	1800	the
B-outcome	1801	1802	6
I-outcome	1802	1803	-
I-outcome	1803	1808	month
I-outcome	1809	1815	follow
I-outcome	1815	1816	-
I-outcome	1816	1818	up
O	1819	1829	assessment
O	1829	1830	,
O	1831	1837	except
O	1838	1841	for
B-outcome	1842	1846	role
I-outcome	1847	1858	functioning
O	1859	1860	(
B-iv-bin-percent	1860	1862	23
I-iv-bin-percent	1862	1863	%
O	1864	1866	vs
B-cv-bin-percent	1867	1869	16
I-cv-bin-percent	1869	1870	%
O	1870	1871	)
O	1871	1872	.

O	1873	1878	These
O	1879	1883	data
O	1884	1891	suggest
O	1892	1896	that
O	1897	1903	health
O	1903	1904	-
O	1904	1911	related
O	1912	1919	quality
O	1920	1922	of
O	1923	1927	life
O	1928	1931	was
O	1932	1941	generally
O	1942	1952	maintained
O	1953	1955	in
O	1956	1960	both
O	1961	1966	study
O	1967	1971	arms
O	1972	1976	over
O	1977	1980	the
O	1981	1987	course
O	1988	1990	of
O	1991	2000	treatment
O	2000	2001	.
